Transitional cell carcinoma (TCC) comprises the majority of bladder cancers accounting for more than 90%. In general, TCC is grouped in high- or low-grade (HG or LG), noninvasive (NI) or invasive (IN) lesions. The biological differences between these groups probably reflect underlying genetic heterogeneity leading to specific pathways of tumor development and progression. Twenty-two TCCs (nine HGIN, three HGNI, one LGIN, nine LGNI) were tested by UroVysion® Bladder Cancer Kit, a fluorescence in situ hybridization assay designed to detect aneuploidy for chromosomes 3, 7, 17 and loss of the 9p21 locus; the test was performed in duplicate on formalin-fixed paraffin-embedded (FFPE) samples and on freshly isolated nuclei (FIN) in order to evaluate the performance of this targeted test in two different materials derived from the same tumor. Although FFPE specimens offer the certainty of histological diagnosis and allow retrospective studies of a large number of sample, conversely fresh tissues are the most reliable for molecular genetic analysis and also provide a comprehensive analysis of the biopsy. At least 100 cells for each preparation were scored and the signals divided according to loss, disomy and gain (number of signals/cell <2; = 2; ≥ 3). Statistical analysis was conducted by means of a Poisson model. The data generated fromFIN material and from FFPE counterpart were generally comparable. However, in HGNI, significant difference was evidenced, except for chromosome 3; conversely, in HGIN, significant difference emerged only for this signal. A second level of comparison was applied on ten TCC (six HGIN, one HGNI, three LGNI) between data derived from array comparative genomic hybridization and UroVysion analysis on different areas of matched FFPE tissues. Our results reflect the high intra-tumor heterogeneity and also showed some shared aberrations that could be interesting for the therapy with monoclonal antibodies

Bentivegna, A., Panzeri, E., Conconi, D., Redaelli, S., Baronchelli, S., Antolini, L., et al. (2011). Looking for the perfect test (if it exists) for the assessment of chromosome alterations in bladder cancer: UroVysion test and microarray-based CGH analysis. CHROMOSOME RESEARCH, 19(suppl 1), S153-S154.

Looking for the perfect test (if it exists) for the assessment of chromosome alterations in bladder cancer: UroVysion test and microarray-based CGH analysis

BENTIVEGNA, ANGELA;PANZERI, ELENA;CONCONI, DONATELLA;REDAELLI, SERENA;BARONCHELLI, SIMONA;ANTOLINI, LAURA;VALSECCHI, MARIA GRAZIA;DALPRA', LEDA
2011

Abstract

Transitional cell carcinoma (TCC) comprises the majority of bladder cancers accounting for more than 90%. In general, TCC is grouped in high- or low-grade (HG or LG), noninvasive (NI) or invasive (IN) lesions. The biological differences between these groups probably reflect underlying genetic heterogeneity leading to specific pathways of tumor development and progression. Twenty-two TCCs (nine HGIN, three HGNI, one LGIN, nine LGNI) were tested by UroVysion® Bladder Cancer Kit, a fluorescence in situ hybridization assay designed to detect aneuploidy for chromosomes 3, 7, 17 and loss of the 9p21 locus; the test was performed in duplicate on formalin-fixed paraffin-embedded (FFPE) samples and on freshly isolated nuclei (FIN) in order to evaluate the performance of this targeted test in two different materials derived from the same tumor. Although FFPE specimens offer the certainty of histological diagnosis and allow retrospective studies of a large number of sample, conversely fresh tissues are the most reliable for molecular genetic analysis and also provide a comprehensive analysis of the biopsy. At least 100 cells for each preparation were scored and the signals divided according to loss, disomy and gain (number of signals/cell <2; = 2; ≥ 3). Statistical analysis was conducted by means of a Poisson model. The data generated fromFIN material and from FFPE counterpart were generally comparable. However, in HGNI, significant difference was evidenced, except for chromosome 3; conversely, in HGIN, significant difference emerged only for this signal. A second level of comparison was applied on ten TCC (six HGIN, one HGNI, three LGNI) between data derived from array comparative genomic hybridization and UroVysion analysis on different areas of matched FFPE tissues. Our results reflect the high intra-tumor heterogeneity and also showed some shared aberrations that could be interesting for the therapy with monoclonal antibodies
Abstract in rivista
Bladder cancer, Fluorescence in situ, hybridization, Array-CGH, Formalin-fixed paraffinembedded, sample;
English
S153
S154
2
DOI del Poster abstracts 10.1007/s10577-011-9215-6
Bentivegna, A., Panzeri, E., Conconi, D., Redaelli, S., Baronchelli, S., Antolini, L., et al. (2011). Looking for the perfect test (if it exists) for the assessment of chromosome alterations in bladder cancer: UroVysion test and microarray-based CGH analysis. CHROMOSOME RESEARCH, 19(suppl 1), S153-S154.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/61413
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
Social impact